Global Adrenocortical Carcinoma Treatment Market Growth (Status and Outlook) 2023-2029

Global Adrenocortical Carcinoma Treatment Market Growth (Status and Outlook) 2023-2029

Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. The causes of primary adrenocortical carcinoma are unknown. However adrenocortical carcinoma can also be secondary cancer. A secondary cancer is what happens when another form of cancer spreads to the adrenal glands. Adrenocortical carcinoma can occur at any age, but there is a bimodal distribution with a first peak at childhood between 1–6 years old and the second peak in the fourth to the fifth decade of life. During the past decade, collaborative efforts have been made to improve the ACC treatment. 

LPI (LP Information)' newest research report, the “Adrenocortical Carcinoma Treatment Industry Forecast” looks at past sales and reviews total world Adrenocortical Carcinoma Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Adrenocortical Carcinoma Treatment sales for 2023 through 2029. With Adrenocortical Carcinoma Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adrenocortical Carcinoma Treatment industry.

This Insight Report provides a comprehensive analysis of the global Adrenocortical Carcinoma Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adrenocortical Carcinoma Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adrenocortical Carcinoma Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adrenocortical Carcinoma Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adrenocortical Carcinoma Treatment.

The global Adrenocortical Carcinoma Treatment market size is projected to grow from US$ 517.7 million in 2022 to US$ 576.8 million in 2029; it is expected to grow at a CAGR of 1.6% from 2023 to 2029.

Some of the key factors that are driving the adrenocortical carcinoma treatment market are increasing the prevalence of cancer, rising government involvement, increasing funding from various government and non-government organizations. Also, ethical acceptance of adrenocortical carcinoma treatment and high unmet needs in some regions are driving the adrenocortical carcinoma treatment market. However, less awareness and high cost involved in treatment are restraining the global adrenocortical carcinoma treatment market. Also, the introduction of generic drugs in some countries is restraining the growth of adrenocortical carcinoma treatment market. Also, despite the high cost involved in R&D, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for adrenocortical carcinoma treatment market.

This report presents a comprehensive overview, market shares, and growth opportunities of Adrenocortical Carcinoma Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma

Segmentation by application
Hospitals
Ambulatory Surgical Centers
Clinics
Cancer Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ArQule
EnGeneIC
Exelixis
Merck
Millendo Therapeutics
Orphagen Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.